Literature DB >> 19853529

Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs.

Robert H Dworkin1, Daniel C Malone, Christopher J Panarites, Edward P Armstrong, Sissi V Pham.   

Abstract

UNLABELLED: Knowledge of the health care costs associated with neuropathic pain is limited. Existing studies have not directly compared the health care costs of different neuropathic pain conditions, and patients with neuropathic pain have not been compared with control subjects with the same underlying conditions (for example, diabetes). To determine health care costs associated with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN), patients with these conditions were selected from 2 different administrative databases of health care claims and respectively matched to control subjects who had a diagnosis of herpes zoster without persisting pain or a diagnosis of diabetes without neurological complications using propensity scores for demographic and clinical factors. Total excess health care costs attributable to PHN and painful DPN and excess costs for inpatient care, outpatient/professional services, and pharmacy expenses were calculated. The results indicated that the annual excess health care costs associated with peripheral neuropathic pain in patients of all ages range from approximately $1600 to $7000, depending on the specific pain condition. Total excess health care costs associated with painful DPN were substantially greater than those associated with PHN, which might reflect the great medical comorbidity associated with DPN. PERSPECTIVE: The data demonstrate that the health care costs associated with 1 peripheral neuropathic pain condition cannot be extrapolated to other neuropathic pain conditions. The results also increase understanding of the economic burden of PHN and painful DPN and provide a basis for evaluating the impact on health care costs of new interventions for their treatment and prevention. Copyright 2010 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853529     DOI: 10.1016/j.jpain.2009.08.005

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  34 in total

1.  Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.

Authors:  Mark S Wallace; Thomas D Marcotte; Anya Umlauf; Ben Gouaux; Joseph H Atkinson
Journal:  J Pain       Date:  2015-04-03       Impact factor: 5.820

Review 2.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Influence of opioid prescribing standards on health outcomes among patients with long-term opioid use: a longitudinal cohort study.

Authors:  Richard L Morrow; Ken Bassett; James M Wright; Greg Carney; Colin R Dormuth
Journal:  CMAJ Open       Date:  2020-12-18

4.  5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France.

Authors:  Florentin Clère; Claire Delorme-Morin; Brigitte George; Malou Navez; Bruno Rioult; Florence Tiberghien-Chatelain; Hervé Ganry
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

5.  The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus.

Authors:  R Har; J W Scholey; D Daneman; F H Mahmud; R Dekker; V Lai; Y Elia; M L Fritzler; E B Sochett; H N Reich; D Z I Cherney
Journal:  Diabetologia       Date:  2013-02-15       Impact factor: 10.122

Review 6.  Topical analgesics for neuropathic pain in the elderly: current and future prospects.

Authors:  Jana Sawynok
Journal:  Drugs Aging       Date:  2014-12       Impact factor: 3.923

Review 7.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

8.  Neuroprotective Effect of Matrine in Mouse Model of Vincristine-Induced Neuropathic Pain.

Authors:  Shuai-Shuai Gong; Yu-Xiang Li; Meng-Ting Zhang; Juan Du; Peng-Sheng Ma; Wan-Xia Yao; Ru Zhou; Yang Niu; Tao Sun; Jian-Qiang Yu
Journal:  Neurochem Res       Date:  2016-08-25       Impact factor: 3.996

9.  Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.

Authors:  Antoni Sicras; Javier Rejas; Ruth Navarro; Albert Planas
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

10.  Painful diabetic peripheral neuropathy: Health care costs and complications from 2010 to 2015.

Authors:  Musa Kiyani; Zidanyue Yang; Lefko T Charalambous; Syed M Adil; Hui-Jie Lee; Siyun Yang; Promila Pagadala; Beth Parente; Susan E Spratt; Shivanand P Lad
Journal:  Neurol Clin Pract       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.